Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.51 |
| ▸ | CA2 | P00918 | 3/20 | 0.43 |
| ▸ | CA12 | O43570 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 9/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.42 |
| ▸ | MEN1 | O00255 | 5/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.42 |
| ▸ | NPC1 | O15118 | 4/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.42 |
| ▸ | STS | P08842 | 1/20 | 0.40 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.40 |
| ▸ | CDK1 | P06493 | 1/20 | 0.40 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.40 |
| ▸ | GSK3A | P49840 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.40 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.40 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3243211 | 0.81 | RAB9A (0.56) | RAB9ACA2CA12SMN1; SMN2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL8530892 | 0.80 | RAB9A (0.50) | RAB9ACA2CA12SMN1; SMN2ALDH1A1 | |
| SCHEMBL30410947 | 0.79 | RAB9A (0.56) | RAB9ACA2CA12SMN1; SMN2ALDH1A1 | |
| SCHEMBL6510217 | 0.79 | STS (0.44) | CA2CA12ALDH1A1STSYAP1 | |
| SCHEMBL14596894 | 0.77 | RAB9A (0.55) | RAB9ACA2CA12SMN1; SMN2ALDH1A1 | |
| SCHEMBL15290694 | 0.76 | RAB9A (0.58) | RAB9ACA2CA12SMN1; SMN2ALDH1A1 | |
| SCHEMBL15290701 | 0.76 | RAB9A (0.62) | RAB9ACA2CA12SMN1; SMN2ALDH1A1 | |
| SCHEMBL13292646 | 0.75 | CYP19A1 (0.43) | SMN1; SMN2ALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL8531145 | 0.75 | RAB9A (0.56) | RAB9ACA2CA12SMN1; SMN2ALDH1A1 | |
| SCHEMBL15290697 | 0.75 | RAB9A (0.56) | RAB9ACA2CA12SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1446388-B1 | 1,2,4-TRIAZOLE DERIVATIVES CONTAINING A SULPHAMATE GROUP AS AROMATASE INHIBITORS | STERIX LTD (GB) | 2013-01-09 | — | — | EP | disclosed |
| EP-1446388-B1 | 1,2,4-TRIAZOLE DERIVATIVES CONTAINING A SULPHAMATE GROUP AS AROMATASE INHIBITORS | STERIX LTD (GB) | 2013-01-09 | — | — | EP | disclosed |
| US-7745472-B2 | Compound | STERIX LIMITED (GB) | 2010-06-29 | — | — | US | disclosed |
| US-20090111862-A1 | Compound | RICHTER GEDEON NYRT. (HU) | 2009-04-30 | — | — | US | disclosed |
| US-7361677-B2 | Polycyclic sulphamate compounds suitable for use as inhibitors of aromatase and/or sulphatase | STERIX, LTD. (GB) | 2008-04-22 | — | — | US | disclosed |
| US-20060241173-A1 | A sulfamate compound, especially a sulfamylated flavone, isoflavone or flavanone, that is an inhibitor of both estrone sulfatase activity and aromatase activity for treating breast and endometrial cancers | STERIX LTD. | 2006-10-26 | — | — | US | disclosed |
| US-7098343-B2 | Polycyclic compounds containing a central trivalent atom to which is attached either direct or indirectly via a linker a two or three ring system and a ring system contining sulphamate group as substituent; steroid sulfatase inhibitor | STERIX, LIMITED (GB) | 2006-08-29 | — | — | US | disclosed |
| US-20060142360-A1 | Compound | RICHTER GEDEON NYRT. (HU) | 2006-06-29 | — | — | US | disclosed |
| EP-1446388-A1 | 1,2,4-TRIAZOLE DERIVATIVES CONTAINING A SULPHAMATE GROUP AS AROMATASE INHIBITORS | Sterix Limited (GB) | 2004-08-18 | — | — | EP | disclosed |
| US-20040019016-A1 | Polycyclic compounds containing a central trivalent atom to which is attached either direct or indirectly via a linker a two or three ring system and a ring system contining sulphamate group as substituent; steroid sulfatase inhibitor | RICHTER GEDEON NYRT. (HU) | 2004-01-29 | — | — | US | disclosed |
| WO-2003045925-A1 | 1,2,4-TRIAZOLE DERIVATIVES CONTAINING A SULPHAMATE GROUP AS AROMATASE INHIBITORS | STERIX LIMITED (GB) | 2003-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111862-A1 | Compound | QPCT, SQOR, SDHA | RAB9A 2278/4885CA2 1641/4885CA12 667/4885 |
| US-20060241173-A1 | A sulfamate compound, especially a sulfamylated flavone, isoflavone or flavanone, that is an inhibitor of both estrone sulfatase activity and aromatase activity for treating breast and endometrial cancers | STS, SULT1E1, CYP19A1 | RAB9A 4071/4885CA2 1885/4885CA12 1717/4885 |
| US-20060142360-A1 | Compound | QPCT, SQOR, SDHA | RAB9A 2278/4885CA2 1641/4885CA12 667/4885 |
| US-20040019016-A1 | Polycyclic compounds containing a central trivalent atom to which is attached either direct or indirectly via a linker a two or three ring system and a ring system contining sulphamate group as substituent; steroid sulfatase inhibitor | STS, CYP21A2, SULT1E1 | RAB9A 4512/4885CA2 375/4885CA12 215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.